We transform the most promising oncology innovations into highly competitive opportunities that benefit patients, researchers, investors, and Ontario's economy. Cancer Breakthroughs. Realized.


We know the business of science.


We bridge the funding gap.

Investment Opportunities

We are the gateway to Ontario's oncology assets.

FACIT Announces Six Finalists for 2020 Falcons' Fortunes Pitch Competition

The pitch competition showcases six Ontario-based entrepreneurial researchers working in the oncology space to pitch their innovative research ideas to a panel of judges.

The 7th annual Falcons’ Fortunes competition will be held in Toronto on Tuesday, February 4, 2020

FACIT Features: Fusion Pharma Attracts $20M USD Commitment from Canada Pension Plan Investment Board

FACIT congratulates Fusion Pharma on securing additional investment from CPPIB, adding to the $105M USD Series B announced in April 2019.

The financing enables the company to continue leveraging strong Ontario science, as well as develop manufacturing and local career opportunities for scientists and trainees... 

FACIT Features: Turnstone Biologics Partners with Takeda on viral immunotherapies for cancer

FACIT congratulates Turnstone Biologics, a startup co-founded by FACIT, and Takeda Pharmaceutical Company Limited on their global collaboration and license agreement.

The strategic collaboration will focus on developing multiple products from Turnstone’s next-gen oncolytic viral immunotherapies, marking an important alliance for both companies in the fight against cancer. 

FACIT Features: OICR's Dr. Trevor Pugh wins $1M award for early cancer detection

FACIT congratulates Dr. Trevor Pugh, OICR’s Director of Genomics and Senior Principal Investigator, on being one of ten winners of the 2019 TD Ready Challenge.

The $1M award will support Dr. Pugh’s development work towards advancing a blood-based diagnostic for early cancer detection, in collaboration with Dr. Raymond Kim of the Princess Margaret Cancer Centre.

FACIT, Triphase Accelerator, Celgene, and OICR to present at Canadian Science Policy Conference 2019

Panel focuses on the recent $1B USD FACIT-Triphase Accelerator-Celgene partnership and its impact on Canadian healthcare commercialization

Titled “Ontario First in the innovation economy: impacts of a $1B USD public-private-partnership (PPP) on Canadian healthcare commercialization”, the panel seeks to highlight the outcomes and key lessons from this unprecedented partnership.

FACIT launches assessment of venture philanthropy models to scale Canadian commercialization of cancer research

Ms. Donna Parr and Dr. Niclas Stiernholm recruited to broaden public/private equity expertise

Scaling FACIT’s impact requires new partners and expanded expertise in the management of investments and equity markets. To that end, FACIT has recruited two seasoned executives through its Executive-in-Residence (EIR) Program.

Latest Tweet / Follow

Contact Us